Company Overview of Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. The company’s lead product includes DEXTENZA, which is in Phase III clinical trial for the treatment of post-surgical ocular inflammation and pain during cataract surgery, as well as for the treatment of allergic conjunctivitis; and in Phase II clinical trial for the treatment of inflammatory dry eye disease. It is also developing OTX-TP, which h...
34 Crosby Drive
Bedford, MA 01730
Founded in 2006
Key Executives for Ocular Therapeutix, Inc.
Founder, Chairman, Chief Executive Officer and President
Total Annual Compensation: $723.7K
Chief Financial Officer and Chief Accounting Officer
Total Annual Compensation: $428.6K
Chief Operating Officer
Total Annual Compensation: $499.0K
Compensation as of Fiscal Year 2015.
Ocular Therapeutix, Inc. Key Developments
Ocular Therapeutix, Inc. - Special Call
Nov 14 16
To discuss the topline results of the recently completed Phase 3 clinical trial of DEXTENZA for the treatment of ocular inflammation and pain following ophthalmic surgery
Ocular Therapeutix™ Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA™
Nov 14 16
Ocular Therapeutix, Inc. announced positive topline results from its phase 3 clinical trial of DEXTENZA™ (dexamethasone insert) 0.4 mg, for the treatment of post-surgical ocular inflammation and pain. DEXTENZA is a product candidate administered by a physician as a bioresorbable intracanalicular insert and designed for drug release to the ocular surface for up to 30 days. The trial successfully met its two primary efficacy endpoints for inflammation and pain, achieving statistically significant differences between the treatment group and the placebo group for the absence of inflammatory cells on day 14 and the absence of pain on day 8, respectively. 52.3%% of patients treated with DEXTENZA showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14, compared to 31.1% of those receiving the placebo vehicle control punctum plug (p< 0.0001). 79.6% of patients treated with DEXTENZA reported absence of pain in the study eye on day 8, compared to 61.3% of those receiving the placebo vehicle control punctum plug (p< 0.0001).
Ocular Therapeutix, Inc. Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-30-2016 03:30 PM
Nov 9 16
Ocular Therapeutix, Inc. Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-30-2016 03:30 PM. Venue: The Lotte New York Palace, 50th St. and Madison Avenue, New York, New York, United States. Speakers: Amarpreet Sawhney, Founder, Chairman, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|